Tolerability of Topical Treatments for Atopic Dermatitis.

Draelos, Zoe D; Feldman, Steven R; Berman, Brian; Olivadoti, Melissa; Sierka, Debra; Tallman, Anna M; Zielinski, Michael A; Ports, William C; Baldwin, Sheryl

Draelos, Zoe D; Feldman, Steven R; Berman, Brian; Olivadoti, Melissa; Sierka, Debra; Tallman, Anna M; Zielinski, Michael A; Ports, William C; Baldwin, Sheryl.

Afiliação

Draelos ZD; Dermatology Consulting Services, High Point, NC, USA. zdraelos@northstate.net.
Feldman SR; Wake Forest School of Medicine, Winston-Salem, NC, USA.
Berman B; Skin and Cancer Associates, Aventura, FL, USA.
Olivadoti M; Pfizer Inc., Collegeville, PA, USA.
Sierka D; Pfizer Inc., New York, NY, USA.
Tallman AM; Pfizer Inc., New York, NY, USA.
Zielinski MA; Pfizer Inc., Collegeville, PA, USA.
Ports WC; Pfizer Inc., Groton, CT, USA.
Baldwin S; Pfizer Inc., San Francisco, CA, USA.

Dermatol Ther (Heidelb) ; 9(1): 71-102, 2019 Mar.

Article em En | MEDLINE | ID: mdl-30680551

Palavras-chave

Application site pain; Application site reaction; Atopic dermatitis; Calcineurin inhibitor; Corticosteroid; Crisaborole; Tolerability; Topical therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google